The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.
In Memoriam: Ronald Olejko—May 4, 1950–Sept. 5, 2021
Ronald Frank Olejko (71)—who many ACR/ARP members knew as the man who managed the smooth planning and execution of the ACR’s annual meeting for more than 40 years—passed away on Sunday, Sept. 5, after a long battle with bladder and kidney cancer. He died peacefully at home with friends and loved ones by his side….
New ACR Subcommittee Will Advance Diversity, Equity & Inclusion
The group’s goals include workforce diversification and inclusive speaker recruitment.
ACR Practice Experts Can Answer Challenging Business Questions
Coding questions and billing compliance are just a few of the issues ACR practice management specialists can help managers and rheumatologists navigate to recoup reimbursement and ensure timely patient treatment.
Supporting Women in Rheumatology
In 2014, four rheumatologists formed a new organization to promote gender equity within the field. Today, the Association of Women in Rheumatology offers training and opportunities in leadership, business development, financial planning and more, as recently highlighted at its annual meeting Aug. 12–15.
Washington Pediatric Rheumatologists Eligible for Loan Forgiveness
The 2021–23 Washington budget enables consideration of pediatric rheumatologists for state loan forgiveness programs during the 2019–21 and 2021–23 cycles, making it the first state to include any rheumatologists in its loan forgiveness programs.
FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…
ACR Guidance on Tocilizumab Allocation During Shortage
In June, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab (Actemra) for treatment of hospitalized COVID-19 adults and children who are receiving systemic corticosteroids and supplemental oxygen. Since this announcement, the tocilizumab manufacturer, Genentech, has not been able to produce enough product to meet the higher demand. The…
20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends
Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
Rheumatology Proud: Fostering an Inclusive Environment in Academic Medicine
Everyone wants to be accepted and feel like they belong. These are innately human traits, and they don’t go away when we leave the grade school playground, high school cafeteria or university quad. We want to feel safe and accepted at work, too, and that feeling is important to professional success and effectiveness. From a…
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 814
- Next Page »